Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01637961 · BASELINE

Baseline characteristics

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      21
    units
    Participants
groups
  1. description
    MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.
    id
    BG000
    title
    MLN8237
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.0
          value
          60.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
    param Type
    NUMBER
    title
    FIGO (International Federation of Gynecology and Obstetrics) Stage - Recurrent/Persistent
    unit Of Measure
    participants
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
    param Type
    NUMBER
    title
    Histologic Type - Leiomyosarcoma
    unit Of Measure
    participants
population Description
Eligible and treated patients.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      21
    units
    Participants
groups
  1. description
    MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.
    id
    BG000
    title
    MLN8237
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.0
          value
          60.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
    param Type
    NUMBER
    title
    FIGO (International Federation of Gynecology and Obstetrics) Stage - Recurrent/Persistent
    unit Of Measure
    participants
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
    param Type
    NUMBER
    title
    Histologic Type - Leiomyosarcoma
    unit Of Measure
    participants
population Description
Eligible and treated patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice